Friday, December 1, 2017

Impact Biomedicines Raises $20M In Financing Tranche

San Diego-based Impact Biomedicines said this morning that it has received a $20M, first tranche of financing, after meeting the first milestone in a previously announced, $90M financing agreement with OBerland Capital. The company said the funding cmae following a positive meeting with the U.S. Food and Drug Administration. Impact Biomedicines had announced the $90M funding agreement in October. Impact Biomedicines is developing treatments for myelofibrosis (MF) and polycythemia vera. The company is led by John Hood, Ph.D.